M5
M55.F MacroGenics Inc
- Market cap
- EUR 132M
- P/E
- -
- P/B
- 3.58x
- ROE
- -80.5%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is M55.F undervalued?
Graham numberThe Graham number of MacroGenics Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
MacroGenics Inc fundamental analysis
No fundamental analysis for MacroGenics Inc yet.
MacroGenics Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About MacroGenics Inc
MacroGenics, Inc., a clinical-stage biopharmaceutical company, discovers, develops, manufactures, and commercializes antibody-based therapeutics for the treatment of cancer in the United States. The company's product pipeline includes lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4 for the treatment of mCRPC and docetaxel that is in phase 2 clinical trials, as well as for the treatment of platinum-resistant ovarian cancer and clear…
Full company profileMacroGenics Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
MacroGenics Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 91.9M | 158M | 60.1M | 64.2M | 105M | 75.6M | 152M | 58.7M | 150M | 150M | 107M |
| Gross Profit | -30.2M | 10.5M | -131M | -131M | 97.8M | 73.0M | 145M | 50.5M | 138M | 113M | - |
| Operating Income | -60.0M | -22.1M | -171M | -177M | -131M | -203M | -121M | -168M | -111M | -72.8M | -94.6M |
| EBITDA | - | -14.9M | -163M | -166M | -119M | - | -108M | 2.02M | -57.4M | -59.6M | -189M |
| Net Income | -58.5M | -19.6M | -171M | -152M | -130M | -202M | -120M | -9.06M | -67.0M | -74.6M | -34.5M |
| EPS | - | -0.53 | -4.05 | -3.10 | -2.31 | -3.30 | -1.94 | -0.15 | -1.07 | -1.18 | -0.54 |
| Balance Sheet | |||||||||||
| Total Assets | 311M | 374M | 332M | 313M | 379M | 335M | 280M | 298M | 262M | 257M | 345M |
| Total Liabilities | 42.5M | 74.6M | 89.3M | 81.9M | 82.9M | 95.6M | 138M | 146M | 146M | 201M | 303M |
| Shareholders' Equity | 269M | 299M | 243M | 231M | 296M | 240M | 142M | 153M | 116M | 55.6M | 42.9M |
| Cash & Short-term Investments | 84.1M | 212M | 220M | 126M | 181M | 123M | 109M | 101M | 183M | 57.2M | 114M |
| Cash Flow | |||||||||||
| Operating Cash Flow | -43.7M | 14.4M | -153M | -134M | -112M | -144M | -87.0M | -78.2M | -68.4M | -81.0M | -153M |
| Capital Expenditure | 11.4M | 29.4M | 25.0M | 4.29M | 5.91M | 6.20M | 3.62M | 1.76M | 3.71M | 1.91M | 2.30M |
| Free Cash Flow | - | -15.0M | -178M | -139M | -118M | -150M | -90.6M | -80.0M | -72.1M | -83.0M | -155M |
| Ratios | |||||||||||
| ROE | -21.8% | -6.6% | -70.6% | -65.8% | -43.8% | -84.3% | -84.3% | -5.9% | -57.7% | -134.2% | -80.5% |
| ROA | -18.8% | -5.2% | -51.6% | -48.6% | -34.3% | -60.3% | -42.7% | -3.0% | -25.6% | -29.1% | -10.0% |
| Net Profit Margin | -63.7% | -12.4% | -285.2% | -236.5% | -123.7% | -267.2% | -78.8% | -15.4% | -44.7% | -49.9% | -32.2% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
MacroGenics Inc dividends
MacroGenics Inc has not paid dividends in the last 9 fiscal years.
Who owns MacroGenics Inc
- Insiders 3.49%
- Institutions 78.25%
- Public & others 18.26%
- Shares outstanding 63.7M
- Free float 56.4M
MacroGenics Inc company profile
- Company name
- MacroGenics Inc
- Ticker
- M55.F
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 293
- Fiscal year end
- December
- Address
- 9704 Medical Center Drive, Rockville, MD, United States, 20850
- Phone
- 301 251 5172
- Website
- macrogenics.com
About MacroGenics Inc
MacroGenics, Inc., a clinical-stage biopharmaceutical company, discovers, develops, manufactures, and commercializes antibody-based therapeutics for the treatment of cancer in the United States. The company's product pipeline includes lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4 for the treatment of mCRPC and docetaxel that is in phase 2 clinical trials, as well as for the treatment of platinum-resistant ovarian cancer and clear cell gynecologic cancer which has completed phase 1 clinical trial; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload; MGC028, an antibody-drug conjugates (ADC) that targets ADAM9 and delivers a novel TOP1i-based linker-payload for the treatment of solid tumors, which is in phase 1 clinical trials; MGC030, a ADC molecule that targets an undisclosed antigen expressed across several solid tumors, which is in preclinical trials. It is also developing T-cell engager programs. The company has collaborations with TerSera Therapeutics LLC; Incyte Corporation; and Gilead Sciences, Inc. MacroGenics, Inc. was incorporated in 2000 and is headquartered in Rockville, Maryland.
MacroGenics Inc management
9- Mr. Eric Blasius RisserCEO, President & Director · born 1973
- Mr. James KarrelsSenior VP & CFO · born 1967
- Dr. Ezio Bonvini M.D.Senior VP of Research & Chief Scientific Officer · born 1954
- Dr. Araba Lamouse-Smith Ph.D.Vice President of Technical Operations
- Mr. Jeffrey Stuart Peters J.D.Senior VP, Corporate Secretary, General Counsel & Corporate Compliance Officer · born 1971
- Mr. Steve HarigSenior Vice President of Human Resources
- Mr. Harish KrishnaswamySenior Vice President of Business Development & Portfolio Planning
- Dr. Frank George Perabo FEBU, M.D., Ph.D.Vice President & Interim Head of Clinical Development · born 1964
- Ms. Beth SmithVP, Controller & Treasurer · born 1968